Alterations in circulating angiogenic and anti-angiogenic factors in type 2 diabetic patients with neuropathy

被引:24
|
作者
Motawi, Tarek Kamal [1 ]
Rizk, Sherine Maher [1 ]
Ibrahim, Ihab Abdel-Rahman [2 ]
El-Emady, Yasmin Farid [3 ]
机构
[1] Cairo Univ, Fac Pharm, Cairo, Egypt
[2] Cairo Univ, Fac Med, Cairo, Egypt
[3] Holding Co Biol Prod & Vaccines, Cairo, Egypt
关键词
vascular endothelial growth factor; soluble endoglin; endothelin-1; mRNA; nitric oxide; diabetic peripheral neuropathy; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE; OXIDATIVE STRESS; GLYCEMIC CONTROL; PERIPHERAL NEUROPATHY; PLASMA ENDOTHELIN; FACTOR EXPRESSION; SOLUBLE ENDOGLIN; GENE-EXPRESSION; HIGH GLUCOSE;
D O I
10.1002/cbf.2987
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diabetic peripheral neuropathy (DPN) is one of the most common diabetic chronic complications. There is an increased attention directed towards the role of angiogenic factors including vascular endothelial growth factor (VEGF) and anti-angiogenic factors including soluble endoglin (sEng) as contributors to diabetic microvascular complications including neuropathy. The purposes of this study were to determine the role of these angiogenesis regulators in the prognosis of DPN. The study group included 60 patients with type 2 diabetes mellitus (T2DM) and 20 clinically healthy individuals. The patients were divided into two groups. Group I included 20 T2DM patients without peripheral neuropathy, and Group II consisted of 40 T2DM patients with DPN. In all groups, plasma VEGF, sEng and endothelin-1 (ET-1), nitric oxide and ET-1 mRNA were estimated. Plasma levels of VEGF, sEng, ET-1 and nitric oxide were significantly elevated in diabetic patients (Groups I and II) compared with healthy control subjects, with a higher increase in their levels in patients with DPN compared with diabetic patients without peripheral neuropathy. Measurement of plasma levels of angiogenesis-related biomarkers in high-risk diabetic patients might identify who later develop DPN, thus providing opportunities for early detection and targets for novel treatments. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:155 / 163
页数:9
相关论文
共 50 条
  • [41] Anti-angiogenic strategies in glioblastoma
    Guillamo, J. -S.
    REVUE NEUROLOGIQUE, 2011, 167 (10) : 662 - 667
  • [42] Anti-angiogenic therapy for osteosarcoma
    Quan, Gerald M. Y.
    Choong, Peter F. M.
    CANCER AND METASTASIS REVIEWS, 2006, 25 (04) : 707 - 713
  • [43] Cancer anti-angiogenic therapy
    Shimizu, K
    Oku, N
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (05) : 599 - 605
  • [44] Responses to anti-angiogenic therapies
    Paller, AS
    JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2000, 5 (01) : 83 - 86
  • [45] Oligosaccharides as anti-angiogenic agents
    Cole, Claire Louise
    Jayson, Gordon C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (03) : 351 - 362
  • [46] Anti-angiogenic function of tocotrienol
    Miyazawa, Teruo
    Shibata, Akira
    Nakagawa, Kiyotaka
    Tsuzuki, Tsuyoshi
    ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 2008, 17 : 253 - 256
  • [47] Sales for anti-angiogenic drugs
    Ribatti, Domenico
    ONCOTARGET, 2017, 8 (24) : 38080 - 38081
  • [48] Anti-angiogenic effect of α-mangostin
    Shiozaki, Tomoko
    Fukai, Miyuki
    Hermawati, Elvira
    Juliawaty, Lia Dewi
    Syah, Yana Maolana
    Hakim, Euis Holisotan
    Puthongking, Ploenthip
    Suzuki, Toshihiro
    Kinoshita, Kaoru
    Takahashi, Kunio
    Koyama, Kiyotaka
    JOURNAL OF NATURAL MEDICINES, 2013, 67 (01) : 202 - 206
  • [49] Anti-angiogenic activities of chitooligosaccharides
    Wu, Haige
    Yao, Ziang
    Bal, Xuefang
    Du, Yuguang
    Lin, Bingcheng
    CARBOHYDRATE POLYMERS, 2008, 73 (01) : 105 - 110
  • [50] COMPLICATIONS OF ANTI-ANGIOGENIC THERAPY
    Brunetto, Andre
    Tan, Daniel
    Yap, Tim
    Olmos, David
    Kaye, Stan
    ANNALS OF ONCOLOGY, 2009, 20 : 24 - 24